We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
In the latest close session, Merck (MRK - Free Report) was down 1.28% at $118.10. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Elsewhere, the Dow saw an upswing of 0.11%, while the tech-heavy Nasdaq depreciated by 0.73%.
Shares of the pharmaceutical company have depreciated by 3.38% over the course of the past month, outperforming the Medical sector's loss of 10.07%, and the S&P 500's loss of 7.34%.
Analysts and investors alike will be keeping a close eye on the performance of Merck in its upcoming earnings disclosure. The company's earnings report is set to go public on April 30, 2026. The company is predicted to post an EPS of -$0.57, indicating a 125.68% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $16.01 billion, up 3.09% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.47 per share and revenue of $66.68 billion, indicating changes of -39.09% and +2.57%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Merck. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.19% increase. Merck is holding a Zacks Rank of #3 (Hold) right now.
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 21.88. Its industry sports an average Forward P/E of 14.41, so one might conclude that Merck is trading at a premium comparatively.
Meanwhile, MRK's PEG ratio is currently 2.18. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.18 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Dips More Than Broader Market: What You Should Know
In the latest close session, Merck (MRK - Free Report) was down 1.28% at $118.10. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Elsewhere, the Dow saw an upswing of 0.11%, while the tech-heavy Nasdaq depreciated by 0.73%.
Shares of the pharmaceutical company have depreciated by 3.38% over the course of the past month, outperforming the Medical sector's loss of 10.07%, and the S&P 500's loss of 7.34%.
Analysts and investors alike will be keeping a close eye on the performance of Merck in its upcoming earnings disclosure. The company's earnings report is set to go public on April 30, 2026. The company is predicted to post an EPS of -$0.57, indicating a 125.68% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $16.01 billion, up 3.09% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.47 per share and revenue of $66.68 billion, indicating changes of -39.09% and +2.57%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Merck. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.19% increase. Merck is holding a Zacks Rank of #3 (Hold) right now.
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 21.88. Its industry sports an average Forward P/E of 14.41, so one might conclude that Merck is trading at a premium comparatively.
Meanwhile, MRK's PEG ratio is currently 2.18. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.18 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.